Fibrosis-related biomarkers and incident cardiovascular disease in older adults the cardiovascular health study

Circulation: Arrhythmia and Electrophysiology

Volumn 7, Issue 4, 2014, Pages 583-589

  Agarwal, Isha ^a   Glazer, Nicole L ^b   Barasch, Eddy ^c   Biggs, Mary L ^d   Djousse, Luc ^f   Fitzpatrick, Annette L ^d   Gottdiener, John S ^g   Ix, Joachim H ^h   Kizer, Jorge R ⁱ   Rimm, Eric B ^a,f   Sicovick, David S ^e   Tracy, Russell P ^j   Mukamal, Kenneth J ^k  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c STONY BROOK UNIVERSITY   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^j UNIVERSITY OF VERMONT   (United States)

^k BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

more..

Author keywords

Cardiovascular diseases; Collagen; Epidemiology; Heart failure

Indexed keywords

C REACTIVE PROTEIN; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; TRANSFORMING GROWTH FACTOR BETA; TROPONIN T; BIOLOGICAL MARKER; COLLAGEN; PEPTIDE FRAGMENT; PROCOLLAGEN; PROCOLLAGEN TYPE III N TERMINAL PEPTIDE; PROCOLLAGEN TYPE III-N-TERMINAL PEPTIDE;

AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COMMUNITY LIVING; DISEASE ASSOCIATION; FEMALE; FIBROGENESIS; GLOMERULUS FILTRATION RATE; GLUCOSE TOLERANCE TEST; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PLEIOTROPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; AGE; AGING; BLOOD; EPIDEMIOLOGY; FIBROSIS; INCIDENCE; MULTICENTER STUDY; PATHOLOGY; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; TIME; UNITED STATES; VERY ELDERLY;

CARDIOVASCULAR DISEASES; COLLAGEN; EPIDEMIOLOGY; HEART FAILURE;

AGE FACTORS; AGED; AGED, 80 AND OVER; AGING; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; FEMALE; FIBROSIS; HEART FAILURE; HUMANS; INCIDENCE; MALE; MYOCARDIAL INFARCTION; PEPTIDE FRAGMENTS; PROCOLLAGEN; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; STROKE; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA; UNITED STATES;

EID: 84907901497     PISSN: 19413149     EISSN: 19413084     Source Type: Journal    
DOI: 10.1161/CIRCEP.114.001610     Document Type: Article

References (50)

1. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol. 2000;35:569-582.
2. Gibbons GH, Dzau VJ. The emerging concept of vascular remodeling. N Engl J Med. 1994;330:1431-1438.
3. Pitt B, Zannad F. The detection of myocardial fibrosis: an opportunity to reduce cardiovascular risk in patients with diabetes mellitus? Circ Cardiovasc Imaging. 2012;5:9-11.
4. Klappacher G, Franzen P, Haab D, Mehrabi M, Binder M, Plesch K, Pacher R, Grimm M, Pribill I, Eichler HG. Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis. Am J Cardiol. 1995;75:913-918.
5. Wang TJ, Larson MG, Benjamin EJ, Siwik DA, Safa R, Guo CY, Corey D, Sundstrom J, Sawyer DB, Colucci WS, Vasan RS. Clinical and echocardiographic correlates of plasma procollagen type III amino-terminal peptide levels in the community. Am Heart J. 2007;154:291-297.
6. Dhingra R, Pencina MJ, Schrader P, Wang TJ, Levy D, Pencina K, Siwik DA, Colucci WS, Benjamin EJ, Vasan RS. Relations of matrix remodeling biomarkers to blood pressure progression and incidence of hypertension in the community. Circulation. 2009;119:1101-1107.
7. Poulsen SH, Høst NB, Egstrup K. Long-term changes in collagen formation expressed by serum carboxyterminal propeptide of type-I procollagen and relation to left ventricular function after acute myocardial infarction. Cardiology. 2001;96:45-50.
8. Glazer NL, Macy EM, Lumley T, Smith NL, Reiner AP, Psaty BM, King GL, Tracy RP, Siscovick DS. Transforming growth factor beta-1 and incidence of heart failure in older adults: the Cardiovascular Health Study. Cytokine. 2012;60:341-345.
9. Velagaleti RS, Gona P, Sundström J, Larson MG, Siwik D, Colucci WS, Benjamin EJ, Vasan RS. Relations of biomarkers of extracellular matrix remodeling to incident cardiovascular events and mortality. Arterioscler Thromb Vasc Biol. 2010;30:2283-2288.
10. Tashiro H, Shimokawa H, Sadamatu K, Yamamoto K. Prognostic significance of plasma concentrations of transforming growth factor-beta in patients with coronary artery disease. Coron Artery Dis. 2002;13:139-143.
11. Barasch E, Gottdiener JS, Aurigemma G, Kitzman DW, Han J, Kop WJ, Tracy RP. Association between elevated fibrosis markers and heart failure in the elderly: the cardiovascular health study. Circ Heart Fail. 2009;2:303-310.
12. Stefoni S, Cianciolo G, Donati G, Dormi A, Silvestri MG, Colì L, De Pascalis A, Iannelli S. Low TGF-beta1 serum levels are a risk factor for atherosclerosis disease in ESRD patients. Kidney Int. 2002;61:324-335.
13. Barasch E, Gottdiener JS, Aurigemma G, Kitzman DW, Han J, Kop WJ, Tracy RP. The relationship between serum markers of collagen turnover and cardiovascular outcome in the elderly: the Cardiovascular Health Study. Circ Heart Fail. 2011;4:733-739.
14. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med. 2000;342:1350-1358.
15. Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, Kronmal RA, Kuller LH, Manolio TA, Mittelmark MB, Newman A. The Cardiovascular Health Study: design and rationale. Ann Epidemiol. 1991;1:263-276.
16. Fredericks S, Holt DW. TGF-beta quantitation can be tricky. Transplantation. 1999;68:468-469.
17. Psaty BM, Kuller LH, Bild D, Burke GL, Kittner SJ, Mittelmark M, Price TR, Rautaharju PM, Robbins J. Methods of assessing prevalent cardiovascular disease in the Cardiovascular Health Study. Ann Epidemiol. 1995;5:270-277.
18. Ives DG, Fitzpatrick AL, Bild DE, Psaty BM, Kuller LH, Crowley PM, Cruise RG, Theroux S. Surveillance and ascertainment of cardiovascular events. The Cardiovascular Health Study. Ann Epidemiol. 1995;5:278-285.
19. Gardin JM, Wong ND, Bommer W, Klopfenstein HS, Smith VE, Tabatznik B, Siscovick D, Lobodzinski S, Anton-Culver H, Manolio TA. Echocardiographic design of a multicenter investigation of free-living elderly subjects: the Cardiovascular Health Study. J Am Soc Echocardiogr. 1992;5:63-72.
20. Gottdiener JS, Arnold AM, Aurigemma GP, Polak JF, Tracy RP, Kitzman DW, Gardin JM, Rutledge JE, Boineau RC. Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol. 2000;35:1628-1637.
21. Psaty BM, Lee M, Savage PJ, Rutan GH, German PS, Lyles M. Assessing the use of medications in the elderly: methods and initial experience in the Cardiovascular Health Study. The Cardiovascular Health Study Collaborative Research Group. J Clin Epidemiol. 1992;45:683-692.
22. Rifkin DE, Katz R, Chonchol M, Fried LF, Cao J, de Boer IH, Siscovick DS, Shlipak MG, Sarnak MJ. Albuminuria, impaired kidney function and cardiovascular outcomes or mortality in the elderly. Nephrol Dial Transplant. 2010;25:1560-1567.
23. März W, Tiran B, Seelhorst U, Wellnitz B, Bauersachs J, Winkelmann BR, Boehm BO; LURIC Study Team. N-terminal pro-B-type natriuretic peptide predicts total and cardiovascular mortality in individuals with or without stable coronary artery disease: the Ludwigshafen Risk and Cardiovascular Health Study. Clin Chem. 2007;53:1075-1083.
24. Lunn M, McNeil D. Applying Cox regression to competing risks. Biometrics. 1995;51:524-532.
25. Bertoluci MC, Uebel D, Schmidt A, Thomazelli FC, Oliveira FR, Schmid H. Urinary TGF-beta1 reduction related to a decrease of systolic blood pressure in patients with type 2 diabetes and clinical diabetic nephropathy. Diabetes Res Clin Pract. 2006;72:258-264.
26. Schaan BD, Quadros AS, Sarmento-Leite R, De Lucca G Jr, Bender A, Bertoluci M. 'Correction:' serum transforming growth factor beta-1 (TGFbeta-1) levels in diabetic patients are not associated with pre-existent coronary artery disease. Cardiovasc Diabetol. 2007;6:19.
27. Pfeiffer A, Middelberg-Bisping K, Drewes C, Schatz H. Elevated plasma levels of transforming growth factor-beta 1 in NIDDM. Diabetes Care. 1996;19:1113-1117.
28. López B, González A, Díez J. Circulating biomarkers of collagen metabolism in cardiac diseases. Circulation. 2010;121:1645-1654.
29. Quilliot D, Alla F, Böhme P, Bruntz JF, Hammadi M, Dousset B, Ziegler O, Zannad F. Myocardial collagen turnover in normotensive obese patients: relation to insulin resistance. Int J Obes (Lond). 2005;29:1321-1328.
30. Dobaczewski M, Chen W, Frangogiannis NG. Transforming growth factor (TGF)-ß signaling in cardiac remodeling. J Mol Cell Cardiol. 2011;51:600-606.
31. Grainger DJ. Transforming growth factor beta and atherosclerosis: so far, so good for the protective cytokine hypothesis. Arterioscler Thromb Vasc Biol. 2004;24:399-404.
32. Pardali E, Ten Dijke P. TGFß signaling and cardiovascular diseases. Int J Biol Sci. 2012;8:195-213.
33. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008;214:199-210.
34. Lan HY. Diverse roles of TGF-ß/Smads in renal fibrosis and inflammation. Int J Biol Sci. 2011;7:1056-1067.
35. Soler EP, Ruiz VC. Epidemiology and risk factors of cerebral ischemia and ischemic heart diseases: similarities and differences. Curr Cardiol Rev. 2010;6:138-149.
36. Toma I, McCaffrey TA. Transforming growth factor-ß and atherosclerosis: interwoven atherogenic and atheroprotective aspects. Cell Tissue Res. 2012;347:155-175.
37. Khan R, Sheppard R. Fibrosis in heart disease: understanding the role of transforming growth factor-beta in cardiomyopathy, valvular disease and arrhythmia. Immunology. 2006;118:10-24.
38. Moulin T, Tatu L, Crépin-Leblond T, Chavot D, Bergès S, Rumbach T. The Besançon Stroke Registry: an acute stroke registry of 2,500 consecutive patients. Eur Neurol. 1997;38:10-20.
39. Martí-Vilalta JL, Arboix A. The Barcelona Stroke Registry. Eur Neurol. 1999;41:135-142.
40. Vemmos KN, Takis CE, Georgilis K, Zakopoulos NA, Lekakis JP, Papamichael CM, Zis VP, Stamatelopoulos S. The Athens stroke registry: results of a five-year hospital-based study. Cerebrovasc Dis. 2000;10:133-141.
41. Fleenor BS, Marshall KD, Durrant JR, Lesniewski LA, Seals DR. Arterial stiffening with ageing is associated with transforming growth factor-ß1-related changes in adventitial collagen: reversal by aerobic exercise. J Physiol. 2010;588(pt 20):3971-3982.
42. On YK, Jeon ES, Lee SY, Shin DH, Choi JO, Sung J, Kim JS, Sung K, Park P. Plasma transforming growth factor beta1 as a biochemical marker to predict the persistence of atrial fibrillation after the surgical maze procedure. J Thorac Cardiovasc Surg. 2009;137:1515-1520.
43. Behnes M, Hoffmann U, Lang S, Weiss C, Ahmad-Nejad P, Neumaier M, Borggrefe M, Brueckmann M. Transforming growth factor beta 1 (TGFbeta 1) in atrial fibrillation and acute congestive heart failure. Clin Res Cardiol. 2011;100:335-342.
44. Kawamura M, Ito H, Onuki T, Miyoshi F, Watanabe N, Asano T, Tanno K, Kobayashi Y. Candesartan decreases type III procollagen-N-peptide levels and inflammatory marker levels and maintains sinus rhythm in patients with atrial fibrillation. J Cardiovasc Pharmacol. 2010;55:511-517.
45. Zhang R, Zhang YY, Huang XR, Wu Y, Chung AC, Wu EX, Szalai AJ, Wong BC, Lau CP, Lan HY. C-reactive protein promotes cardiac fibrosis and inflammation in angiotensin II-induced hypertensive cardiac disease. Hypertension. 2010;55:953-960.
46. Sharma K, Ix JH, Mathew AV, Cho M, Pflueger A, Dunn SR, Francos B, Sharma S, Falkner B, McGowan TA, Donohue M, Ramachandrarao S, Xu R, Fervenza FC, Kopp JB. Pirfenidone for diabetic nephropathy. J Am Soc Nephrol. 2011;22:1144-1151.
47. Sivakumar P, Das AM. Fibrosis, chronic inflammation and new pathways for drug discovery. Inflamm Res. 2008;57:410-418.
48. Ban CR, Twigg SM. Fibrosis in diabetes complications: pathogenic mechanisms and circulating and urinary markers. Vasc Health Risk Manag. 2008;4:575-596
49. Krum H, Elsik M, Schneider HG, Ptaszynska A, Black M, Carson PE, Komajda M, Massie BM, McKelvie RS, McMurray JJ, Zile MR, Anand IS. Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy. Circ Heart Fail. 2011;4:561-568.
50. Richeldi L, du Bois RM. Pirfenidone in idiopathic pulmonary fibrosis: the CAPACITY program. Expert Rev Respir Med. 2011;5:473-481.